P942 Real-world data on outcomes of treatment with ustekinumab in patients with Ulcerative Colitis

P942 Real-world data on outcomes of treatment with ustekinumab in patients with Ulcerative Colitis

Abstract Background Ustekinumab (UST), a monoclonal antibody against the shared p40 subunit of IL-12/IL-23, has been approved for the treatment of moderate to severe ulcerative colitis (UC). The aim of this ambi-directional study is to collect and analyze data from a large cohort of Greek patients w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Crohn's and colitis 2024-01, Vol.18 (Supplement_1), p.i1715-i1716
Hauptverfasser: Chalakatevaki, K, Kokkotis, G, Chatzinikolaou, M L, Anagnostopoulou, E, Argiriou, K, Viazis, N, Galanopoulos, M, Gerasimatos, G, Giouleme, O, Zampeli, E, Zacharopoulou, E, Theodoropoulou, A, Theocharis, G, Kalogirou, M, Karatzas, P, Karmiris, K, Kapsoritakis, A, Koustenis, K, Koutroumpakis, I, Kiriakos, N, Lazou, D, Liatsos, C, Mantaka, A, Mantzaris, G, Michalopoulos, G, Michopoulos, S, Orfanidou, A, Papathanasiou, E, Polymeros, D, Potamianos, S, Sotiropoulos, C, Soufleris, K, Tzouvala, M, Foteinogiannopoulou, K, Chatzidakis, A, Psistakis, A, Bamias, G
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Ustekinumab (UST), a monoclonal antibody against the shared p40 subunit of IL-12/IL-23, has been approved for the treatment of moderate to severe ulcerative colitis (UC). The aim of this ambi-directional study is to collect and analyze data from a large cohort of Greek patients with UC treated with UST. Methods Data from UC patients treated with UST in 15 Greek hospitals were analyzed to evaluate rates of clinical response (CR, 50% reduction in UC-PRO2 compared to baseline) at week 16 of treatment, steroid-free clinical remission (SFCRem, pMAYO score
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjad212.1072